text:
To remove the grille from your Alpha B1 speakers, insert a hook into one of the holes in the grille close to a corner and lightly pull on it. It is best to work your way around the grille at each corner when removing it. If you just pull on one corner to remove it, you may end up bending the grille.
PSB Offers a grille hook tool to assist. Please submit a request below to contact our Support Team to learn how to acquire one.
NOTE: The Alpha B1 and Alpha B use an identical metal grille though the model logo will differ.


text: Julian Sas' new studio album is called Bound To Roll. Like a big freight train the Dutch blues-rocker adds in the album's title track and that's a pretty accurate description of his approach to making music. Honest, unstoppable, never looking back, accelerator on the floor With a Gretch, a Fender or a Gibson, using fingers or a pick, a moving ballad or a heavy rocker, Julian and his musicians Tenny Tahamata (bass) and Rob Heijne (drums) only recognise one level of commitment and that is always much more than 100%. That drive combined with great musicianship made Sas and his compadres into a phenomenon; a top act with a large fanatical following, respected by fellow musicians and a welcome guest in sold-out venues and on festivals throughout Europe. And Sas himself arguably into Europe's best blues guitarist and a very soulful lead-vocalist. Already way back in 1999 Julian Sas and his band were headlining the legendary Fehmarn Festival, a German Woodstock equivalent dedicated to Jimi Hendrix. Another hero of Julian is Irishman Rory Gallagher. Not only was Sas many times top-of-the-bill at Festivals held in his honour, he also stepped almost in literally in Rory's hoes. Several times as a matter of fact. Like headlining the annual Rory Gallagher Tribute Festival in Ballyshannon, Co. Donegal, Ireland, Rory's place of birth. Sas also performed more than once with the former members of Gallagher's band. Bound to Roll, Julian Sas' eight studio album, is a record that took time to make. More than two-and-a-half years, tells the Dutch blues man, I had tons of ideas and was writing constantly but a lot of that went straight into the bin. 'Bound to Roll' is a very personal record. This album is about pleasure, enjoyment, love, loss, pain and sadness. About real life, about the blues, about experiences that, I hope, made me stronger and a better human being. For me making this album was a way of dealing with my emotions. Besides 9 new Sas originals, Bound to Roll also features three covers; Rory Gallagher's Shadow Play, Bob Dylan's Highway 61 Revisited and Humble Pie's 30 Days In The Hole (their seventh single and also included on their Smokin' album) About the choice of these songs Julian explains: 'Shadow Play' totally reflects my feelings about the recent period of my life. Especially the text. The song fits perfectly with my own songs. Dylan's 'Highway 61 Revisited', is just a killer song, the groove, the lyric - everybody needs to get rid of something on Highway 61, personal or other. This is also the track that made me fall in love with playing slide. '30 Days In The Hole'; Steve Marriott is one of my favourite singers and writers. This song I wanted to record because of the aggression of the riff, a lot of anger, one of the greatest rock-riffs ever. All great songs to play! Bound To Roll is an album Julian Sas and his partners Tenny Tahamata and Rob Heijne should be proud of. It's a riveting listen and bursting to the gills with craftsmanship, inventive playing and emotion. The blues as it should be.

industry_corpus2: Film & Entertainment


text:
Construct extension to existing care home to provide school facilities.
The existing Care Home remained occupied throughout the construction period. Particular care and attention required to ensure safety and wellbeing of children and staff. Essential to ensure completed project on time and in accordance with LA requirements.

industry_corpus2: Real Estate & Construction


text: Full length print jersey dress. The perfect holiday piece. Comfortable and easy care! 96% viscose 4% elastane.

industry_corpus2: Manufacturing


text:
McIntyre appeared in nine games in her first season with CSUN ... averaged 0.4 points, 0.2 rebounds and 0.8 assists in 36 minutes of action for the year ... knocked down only field goal of the season, a 3-pointer, at Arizona on Feb. 16 ... posted season-high two rebounds, three assists and nine minutes against Cal State Bakersfield on Jan. 11 ... had a free throw at Cal Poly on Feb. 20 ... recorded a steal at Arizona on Feb. 16.
McIntyre played both basketball and softball for the Knights ... earned all-league honors following sophomore year ... graduated in 2009.
Born on Dec. 5, 1990 ... daughter of Charlotte Goodman ... stepfather is David Goodman ... has two sisters, Chelsea and Bryanna ... Chelsea is a goalkeeper at the University of Arizona ... favorites include the LA Lakers, New Orleans Hornet Chris Paul, actor Channing Tatum and and the movies "Love and Basketball" and "Glory Road" ... says the best advice she has been given is that "the only person that can stop you from achieving your goals is yourself" ... says her mother is a greatest hero ... majoring in Broadcast Journalism.

industry_corpus2: Sports


text:
Pacific Sound Radio is a guest driven music program focused on providing a platform for local artists to share their stories, and showcase their unique personalities with the goal to foster and grow support for the Vancouver music scene.
Founded in July of 2017, creators James Olson and Jaeden Froese had one goal in mind, to transform Vancouver into a premiere music hotspot. Drawing from a shared love of local music and a growing network of musicians, Olson, Froese, and co-host Travis Noel bring you a show that uncovers the ever expanding variety of up and coming bands and artists on the West Coast.


text:
The real difference between Paganism and Christianity is perfectly summed up in the difference between the pagan, or natural, virtues, and those three virtues of Christianity which the Church of Rome calls virtues of grace. The pagan, or rational, virtues are such things as justice and temperance, and Christianity has adopted them. The three mystical virtues which Christianity has not adopted, but invented, are faith, hope, and charity. Now much easy and foolish Christian rhetoric could easily be poured out upon those three words, but I desire to confine myself to the two facts which are evident about them. The first evident fact (in marked contrast to the delusion of the dancing pagan)–the first evident fact, I say, is that the pagan virtues, such as justice and temperance, are the sad virtues, and that the mystical virtues of faith, hope, and charity are the gay and exuberant virtues. And the second evident fact, which is even more evident, is the fact that the pagan virtues are the reasonable virtues, and that the Christian virtues of faith, hope, and charity are in their essence as unreasonable as they can be.
It is somewhat amusing, indeed, to notice the difference between the fate of these three paradoxes in the fashion of the modern mind. Charity is a fashionable virtue in our time; it is lit up by the gigantic firelight of Dickens. Hope is a fashionable virtue to-day; our attention has been arrested for it by the sudden and silver trumpet of Stevenson. But faith is unfashionable, and it is customary on every side to cast against it the fact that it is a paradox. Everybody mockingly repeats the famous childish definition that faith is “the power of believing that which we know to be untrue.” Yet it is not one atom more paradoxical than hope or charity. Charity is the power of defending that which we know to be indefensible. Hope is the power of being cheerful in circumstances which we know to be desperate. It is true that there is a state of hope which belongs to bright prospects and the morning; but that is not the virtue of hope. The virtue of hope exists only in earthquake and, eclipse. It is true that there is a thing crudely called charity, which means charity to the deserving poor; but charity to the deserving is not charity at all, but justice. It is the undeserving who require it, and the ideal either does not exist at all, or exists wholly for them. For practical purposes it is at the hopeless moment that we require the hopeful man, and the virtue either does not exist at all, or begins to exist at that moment. Exactly at the instant when hope ceases to be reasonable it begins to be useful. Now the old pagan world went perfectly straightforward until it discovered that going straightforward is an enormous mistake. It was nobly and beautifully reasonable, and discovered in its death-pang this lasting and valuable truth, a heritage for the ages, that reasonableness will not do. The pagan age was truly an Eden or golden age, in this essential sense, that it is not to be recovered. And it is not to be recovered in this sense again that, while we are certainly jollier than the pagans, and much more right than the pagans, there is not one of us who can, by the utmost stretch of energy, be so sensible as the pagans. That naked innocence of the intellect cannot be recovered by any man after Christianity; and for this excellent reason, that every man after Christianity knows it to be misleading. Let me take an example, the first that occurs to the mind, of this impossible plainness in the pagan point of view. The greatest tribute to Christianity in the modern world is Tennyson’s “Ulysses.” The poet reads into the story of Ulysses the conception of an incurable desire to wander. But the real Ulysses does not desire to wander at all. He desires to get home. He displays his heroic and unconquerable qualities in resisting the misfortunes which baulk him; but that is all. There is no love of adventure for its own sake; that is a Christian product. There is no love of Penelope for her own sake; that is a Christian product. Everything in that old world would appear to have been clean and obvious. A good man was a good man; a bad man was a bad man. For this reason they had no charity; for charity is a reverent agnosticism towards the complexity of the soul. For this reason they had no such thing as the art of fiction, the novel; for the novel is a creation of the mystical idea of charity. For them a pleasant landscape was pleasant, and an unpleasant landscape unpleasant. Hence they had no idea of romance; for romance consists in thinking a thing more delightful because it is dangerous; it is a Christian idea. In a word, we cannot reconstruct or even imagine the beautiful and astonishing pagan world. It was a world in which common sense was really common.

industry_corpus2: Others


text:
Macdonald, S.D.. "Quail". The Canadian Encyclopedia, 04 March 2015, Historica Canada. https://www.thecanadianencyclopedia.ca/en/article/quail. Accessed 22 April 2019.
Quail is the name most commonly applied to an Old World species, Coturnix coturnix, of chickenlike birds.
The northern bobwhite, unlike the other two species of quail in Canada, lacks an ornamental crest (Macmillan Illustrated Animal Encyclopedia).
Quail is the name most commonly applied to an Old World species, Coturnix coturnix, of chickenlike birds, which migrate seasonally in vast flocks and have long been an important human food source, eg, for the Israelites in the wilderness. New World quail are the only members of a subfamily native to the Americas. New World quail are not migratory. Some are adapted to desert habitats and can survive indefinitely without water if succulent food is available.
In Canada, 3 species are found: California quail (Callipepla californica) and mountain quail (Oreortyx pictus) in the mildest parts of southern BC; northern bobwhite (Colinus virginianus) is native to southern Ontario. The now endangered northern bobwhite is the best-known species and, in the US, is the most widely hunted game bird. It has been introduced unsuccessfully in several parts of southern Canada. Unlike the other 2, it lacks an ornamental crest.

industry_corpus2: Agriculture & Fisheries


text:
What are the rights of people with a disability?
More recently the Convention on the Rights of Persons with Disabilities explained how human rights relate specifically for people with disabilities.
To have equal access to public spaces, amenities, travel and information.
All disability service providers must abide by a set of Standards (rules and guidelines), to make sure people with a disability are receiving good quality. This is a brief summary of each of the six National Standards for Disability Services. You should expect these standards from any disability service you use. ON-Q strives to exceed these standards in every service we provide.
1. RIGHTS: You are supported to uphold and protect your rights. In particular, you have the right to make your own decisions about the supports you want to receive.
2. PARTICIPATION & INCLUSION: You can take part in the community in ways that are important to you and that make you feel included.
3. INDIVIDUAL OUTCOMES: You are listened to about what you want to achieve. You feel supported to make decisions on how to achieve your goals.
4. FEEDBACK & COMPLAINTS: You have a say about what works and what doesn’t work in the service you receive. You have a say about how the service could be improved. You are free to make a complaint if you are not satisfied with the service.
5. SERVICE ACCESS: Access to the service is fair. It is clear what services and supports are available to you. You are supported with other options if you are not eligible for the service or you feel it is not suitable for you.
6. SERVICE MANAGEMENT: You receive services that are well-planned and well-delivered.
What role does your service provider play in protecting your rights?
To treat all service-users with respect, and without any form of discrimination.
To not violate your human rights.
Wherever possible, to prevent others from violating your human rights, including co-workers, employers, family and the general public.
To put in place preventative measures to protect abuses occurring.
To help service users to understand their rights.
To speak up when they see or hear a person not respecting another’s rights.
To promote to others the importance of upholding human rights (disability rights in particular).
Take positive steps to support people to experience the same human rights as everyone else.
To report and/or address breaches that they become aware of.
To support people with disability to access professional advice, support or advocacy services.
You can raise this with your ON-Q consultant / planner, if you feel comfortable to do so. If you would rather speak to someone else, ask to speak to ON-Q’s Operations Manager or Quality Manager.
You can make a complaint, either in writing, by phone or in person. If you prefer you can email info@onqhr.com.au and we will get back to you. All complaints will be recorded in our complaints register and followed up by the appropriate manager until investigated and addressed.
For more information about giving your feedback or making a complaint, ask an ON-Q staff member for a copy of our Feedback and Complaints Policy.


text:
Dr. William Cho is a Chartered Scientist granted by the Science Council (UK) and a fellow member of several institutes, including the Institute of Biomedical Science (UK), Hong Kong Institute of Biomedical Science and Hong Kong Society for Molecular Diagnostic Sciences. Besides, Dr. Cho being a Guest Professor in several Universities, he is also a registered Chinese medicine practitioner. He has published over 300 papers and book chapters covering cancer biomarkers, proteomics and microRNAs. His main research interests involve focusing on cancer studies by utilizing high-throughput technologies to discover biomarkers for cancer diagnosis, treatment prediction and prognostication.
Dr. Miller received his Ph.D. in 1979 from the University of Texas, did a postdoc in dopamine electrophysiology at UT Southwestern until 1982, followed by a second postdoc in circadian neurobiology at UC Riverside and UC Davis until 1987. From 1982-1987 he also served as a NASA space shuttle project director. Dr. Miller was a research associate in the Stanford Biology Department from 1987-1994 and the Director of Neurochemistry in the Stanford-Upjohn Center for the Study of Sleep and Circadian Rhythms. He was a faculty member in the Department of Pharmacology, Texas Tech Health Sciences Center from 1994 until 2000.From 2000 to 2013 he was an associate professor in the Department of Cell and Neurobiology at the Keck School of Medicine at USC. In March 2013 he accepted a position as Chair of Pharmacology at the American University of the Caribbean School of Medicine where he continues to work.
Suowen Xu, Ph.D., is a natural product pharmacologist. Dr. Xu received his Ph.D. did postdoc studies in biochemistry at NHLBI/NIH, followed by a second postdoc in vascular biology at University of Rochester. Currently, Dr. Xu is Research Assistant Professor of Medicine at University of Rochester. He is a principal investigator interested in identifying novel therapeutic targets and molecular interventions of cardiovascular diseases. He was also an adjunct faculty member (Associate Professor) in the School of Pharmacy, The University of Queensland. He is an editorial board member of 4 journals and serves as reviewers for over 50 journals.
Nelson S. Yee, M.D., Ph.D., F.A.C.P. R.Ph. is the Team Leader of Gastrointestinal Oncology at Penn State Cancer Institute. Dr. Yee received undergraduate education at Massachusetts College of Pharmacy. He then pursued medical education and graduate research training at Cornell University Medical College and Memorial Sloan-Kettering Cancer Center. At Hospital of the University of Pennsylvania, he underwent clinical training in Internal Medicine, Hematology, and Medical Oncology. Currently, Dr. Yee is Associate Professor of Medicine at Pennsylvania State University. He is the principal investigator of clinical studies for new treatment as well as cancer biomarkers and targets in cancer of digestive organs.
Professor Akira Sugawara belongs to the Department of Molecular Endocrinology, Tohoku University Graduate School of Medicine, Sendai, Japan. He graduated from Tohoku University School of Medicine on 1987 (M.D.), and got Ph.D. on 1991 from Tohoku University Graduate School of Medicine. He performed Postdoctoral Fellowship in William Chin’s laboratory at the Women’s Hospital/Harvard Medical School in Boston from 1991 to 1994. His major is general internal medicine, endocrinology and metabolism and hypertension and nephrology. His research interest is 1) molecular biology of nuclear hormone receptors, 2) etiology of high blood pressure, 3) pathophysiology of diabetic nephropathy, 4) gene regulation of aldosterone synthase, and 5) epigenetics of hypertension and diabetes mellitus.
Prof. Dr. Esra Küpeli Akkol was born in Turkey. She got her Bachelor of Science degree in Faculty of Pharmacy, Gazi University, Turkey and got her Ph.D. degree in Pharmacognosy Department from the University of Gazi. She is currently Professor in the Gazi University, Faculty of Pharmacy, Department of Pharmacognosy. Sheserved in manycapacities in her fieldincluding service on several editorial boards and numerous review committees for journal ssuch as Journal of Ethnopharmacology, Journal of Pharmacy Sciences, The Internet Journal of HerbalandPlantMedicine, International Journal of GenuineTraditionalMedicine, Advances in Pharmacological Sciences, Evidence Based Complementary Alternative Medicine and The Open Pain Journal. She has conducted 41 projects and 11 thesis in Gazi University. She has 158 published articles in SCI International Journals, 13 articles in National Journals and 10 chapters in International books.
Dr. Allen is a Professor at the Oregon Institute of Occupational Health Sciences and the Department of Behavioral Neuroscience at the Oregon Health & Science University. He received his Ph.D. in Pharmacology from University of Texas Southwestern Medical Center at Dallas. He has authored more than 75 manuscripts and six reviews. The research in his lab focuses on understanding how neurons in the hypothalamic suprachiasmatic nucleus (SCN) the master circadian oscillator generate circadian timing signals and entrain to the environmental light-dark cycle. We use single-cell electrophysiological recordings, long-term measurements of behavior, and long-term live cell imaging methods to study the signaling pathways in the neural network of SCN neurons and how those contribute to the synchronization of individual SCN oscillators.
Prof. Rosa Amoroso completed the degree in Pharmaceutical Chemistry and Technology and the PhD in Organic Chemistry at University of Bologna. Nowadays she is Associate Professor of Medicinal Chemistry at University of Chieti, Italy. The scientific interests of Prof. Rosa Amoroso are mainly directed towards medicinal chemistry and the research topics are compunds active on Peroxisome proliferator-activated receptors (PPAR), Nitric Oxide Synthase (NOS), and aromatase.
Dr. Balakumar Pitchai is currently working as a Professor of Pharmacology in JKK Nattraja College of Pharmacy, Tamilnadu, India. Previously he was a Senior Associate Professor and Head of Pharmacology Unit at the Faculty of Pharmacy, AIMST University, Bedong, Malaysia. Dr. Balakumar obtained M.Pharm and Ph.D degrees in Pharmacology from Punjabi University, Patiala, India. He was a Visiting Scientist at the University of Montreal, Canada in 2009. He has a vast teaching, research and editorial experiences in the field of Cardiovascular Sciences, and trained several graduates. Dr. Balakumar published around 100 scientific papers in the areas of Cardiovascular, Diabetic and Renal Pharmacology. His papers have been cited for more than 2100 times (SCOPUS), and his ‘H Index’ is 30 (SCOPUS). Dr. Balakumar received “Naranjan S. Dhalla Award” from the International Society of Heart Research (ISHR) and International Academy of Cardiovascular Sciences (IACS) in 2007. Along with Dr. Jagadeesh and Dr. Khin of US FDA, Dr. Balakumar has edited a reference book titled ‘Pathophysiology and Pharmacotherapy of Cardiovascular Disease’ published by the Springer in 2015. He has also edited Special Issues in the areas of Renin-Angiotensin System, PPARs for the Journals namely Pharmacological Research and Current Molecular Pharmacology.
Dr. Blanton obtained a doctorate (Ph.D.) in Biology/Biochemistry from the University of California, Santa Cruz, followed by postdoctoral training at Washington University School of Medicine, St. Louis, MO and at Harvard Medical School, Boston, MA. Currently Dr. Blanton is a Professor and Vice-Chair in the Department of Pharmacology and Neuroscience at Texas Tech University Health Sciences Center, Lubbock, TX. Dr. Blanton is also a Senior Associate Dean in the Graduate School of Biomedical Sciences and director of the MD/PhD Program and the Center for Membrane Protein Research. Dr. Blanton’s research focus is on the structure/function of ligand-gated ion channels, in particular neuronal nicotinic acetylcholine receptors (nAChRs).
Dr. Tracey Bradshaw joined the Experimental Cancer Chemotherapy group within the Cancer Research Laboratories, University of Nottingham in 1993. Now an assistant professor within the School of Pharmacy, her specific research interests lie in the discovery and development of novel anticancer therapeutics embracing NCEs, natural products, nano-medicines and gelators. Research activities within the field of cancer pharmacology include determination of anticancer activity and elucidation of molecular targets and mechanisms of action of novel preclinical antitumour agents. Such research led to clinical evaluation of Phortress and >90 publications. She is a member of the Drug Discovery Group, PAMM, EORTC and EACR.
Dr. Buolamwini obtained a doctorate (Ph.D.) in Pharmaceutical Sciences from the University of Alberta, Canada. Currently Dr. Buolamwini a Professor in the Department of Pharmaceutical Sciences, College of Pharmacy, Rosalind Franklin University of Medicine and Science. He has published more than 70 scientific publications, edited two books, and is a named inventor of 4 issued U.S patents. Dr. Buolamwini was the founding Editor-in-Chief (2001-2013) of Current Cancer Drug Targets, published by Bentham Science Publishers.
Félix Carvalho, PharmD, PhD, is Full Professor of Toxicology, at the Department of Biological Sciences, Laboratory of Toxicology, Faculty of Pharmacy at University of Porto (FFUP), and researcher of the Research Unit on Applied Molecular Biosciences (UCIBIO), Portugal. He is presently the Vice-President of the Portuguese Society of Pharmacology, Vice-director of UCIBIO and Secretary-General of EUROTOX. During the past 27 years, Félix Carvalho has published over 315 scientific articles / book chapters and is co-editor of two Books in the area of Toxicology.
Dr. Guoxun Chen obtained his BS and MS degrees in the Department of Virology and Molecular Biology at Wuhan University, Wuhan, China. He completed his Ph.D degree in the Department of Biochemistry and Molecular Biology at the University of Texas Southwestern Medical Center at Dallas in 2001. After that, Dr. Chen entered the Department of Molecular Genetics at the University of Texas Southwestern Medical Center for the postdoctoral training. In 2006, he became a faculty member in the Department of Nutrition at the University of Tennessee at Knoxville. Now, he is a tenured associated professor at the University of Tennessee. Since the establishment of his independent research lab in 2006, Dr. Chen has focused on the roles of vitamin A in the development of metabolic diseases such as obesity and diabetes, and the regulation of glucose and lipid homeostasis.
Dr. Chow currently is a Professor and Vice Chair in the Department of Molecular and Medical Pharmacology, UCLA School of Medicine. Dr. Chow¹s research is on the molecular mechanism of retroviral DNA integration, a process essential for reproduction of human immunodeficiency virus (HIV) and other retroviruses. Dr. Chow has developed simple in vitro assays for understanding the mechanism of the integration process and screening for new anti-retroviral drugs. Dr. Chow¹s laboratory is also interested in determining the functional role of HIV integrase during reverse transcription and particle assembly, as well as improving retrovirus-based vectors as a vehicle for gene delivery in mammalian cells.
Dr. Civelli is Professor and Chair of the Department of Pharmacology at University of California, Irvine. He holds the Eric L and Lila D Nelson Chair of Neuropharmacology. Previously he was vice president at F. Hoffmann-La Roche, Basel. He is a recognized leader in the field of neuropsychopharmacology. He was the first to clone the D2 dopamine receptor and discovered the diversity of the dopamine receptors, in particular the D4 receptor. He spearheaded reverse pharmacology and used it to discover the first new neuropeptide identified by this approach, nociceptin/orphanin FQ and later neuropeptide S. He discovered the receptors for melanin concentrating hormone and for urotensin II. His primary interest is the study of neuropsychiatric disorders, in particular schizophrenia. He has authored more than 200 manuscripts and holds 30 patents.
Ricardo Jorge Dinis-Oliveira completed a PhD degree in Toxicology in the University of Porto. By Rector Dispatch awarded the European PhD. He holds 2 Post-Doc in Pharmacology and Toxicology and Habilitation (Aggregation) in Forensic Sciences by the Faculty of Medicine, University of Porto. He published more than 90 papers, 20 book chapters, edited three books and 4 patents. He is Director of the Course in Forensic Laboratorial Sciences, Course in Biomedical Sciences and of the Master in Forensic Sciences and Laboratory Techniques of University Institute of Health Sciences. He is the president elect of the Portuguese Association of Forensic Sciences.
Scott T. Eblen, PhD, earned a BS in Biology from the University of Kentucky and a PhD from Vanderbilt University, performing his dissertation research both at Vanderbilt and the Mayo Clinic. He did postdoctoral work at the University of Virginia in the area of signal transduction by protein kinases. He is currently an Associate Professor of Cell and Molecular Pharmacology and Experimental Therapeutics at the Medical University of South Carolina in Charleston, SC. His lab studies signal transduction by protein kinases, E3 ubiquitin ligases, and mRNA splicing in the context of cancer and molecular mechanisms of drug resistance.
Dr Elion obtained a doctorate (Ph.D,) in Biochemistry from the Albert Einstein College of Medicine of Yeshiva University snd is a Professor in the Department of Biological Chemistry and Molecular Pharmacology at Harvard Medical School of Harvard University.
Dr. Fishel obtained her Ph.D. degree (in 2001) in Biochemistry and Molecular Biology from Indiana University School of Medicine, Indianapolis, IN, USA. Dr. Fishel is currently Assistant Professor (Pediatrics, Hematology/Oncology) at Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine. Her research interests have been in exploring rationale molecular targets in difficult-to-treat, refractive cancers, such as pancreatic cancer as well as glioblastoma and pediatric leukemia. Dr. Fishel, as an author/co-author, has published more than 50 articles in various journals, having over 1,655 total citations.
Dr. Dwight German received his Ph.D. training in neuroscience at the University of Oklahoma Health Sciences Center and went on to do post-doctoral work in the Department of Physiology & Biophysics and the Regional Primate Research Center at the University of Washington. He is currently a Professor in the Department of Psychiatry at the University of Texas Southwestern Medical Center. His research focuses on neurodegenerative and neurodevelopmental disorders using both post-mortem human tissues and animal models. His research also focuses on developing blood biomarkers for neurodegenerative/neurodevelopmental disorders.
The research in my laboratory for the past 30 years has been directed towards the areas of experimental chemotherapy and radiotherapy in cancer, with a primary focus on breast cancer and lung cancer. Work has been largely focused on sensitization of lung cancer and breast cancer to radiotherapy and chemotherapy. These efforts have also served to define autophagy and senescence (rather than apoptosis) as primary responses to both chemotherapy and radiotherapy in solid tumor cell models. We have established the existence of cytostatic and cytotoxic functions of autophagy in lung cancer cells and breast cancer cells while recent work has also identified a non-protective form of autophagy that is critical to understanding why efforts towards chemosensitization and radiosensitization via autophagy inhibition may prove to be particularly challenging in the absence of appropriate predictive biomarkers. Current work is focused on approaches for establishing the reversibility of senescence both in cell culture and tumor bearing animal models, with the longer term goal of understanding the role of senescence in sensitivity (or refractoriness) to therapy in breast and lung cancer.
Dr. Wael M Abdel-Rahman (Hassan); MBBCH, MSc (Pathology), PhD (Molecular Pathology) is the coordinator of the MSc/PhD program in Molecular Medicine, College of Medicine and Associate Professor at the College of Health Sciences, University of Sharjah. He is one of the inaugurating researchers of the Sharjah Institute of Medical Research. He is the chair of the College Research Committee and ex-member of the University Postgraduate Studies Council. He is a board member of many scientific journals and conferences and acted as a referee in many awards and grants.
Peng Huang, M.D., Ph.D., is a professor at the University of Texas MD Anderson Cancer Center, Houston, Texas. He received his medical degree at Sun Yat-sen University School of Medicine and his PhD degree from the University of Texas Graduate School of Biomedical Sciences at Houston. Dr. Huang’s research interests are in the areas of cancer metabolism, ROS/redox biology, and anticancer agents. In particular, his laboratory investigates the mechanistic links between oncogentic signals, mitochondrial alterations, and changes in cellular metabolism and drug sensitivity. He has over 160 publications including high-impact articles that are frequently cited. Prof. Huang is currently Associate Editor of Molecular Cancer and a member of editorial boards of multiple scientific journals.
Dr. Kelley is the Betty and Earl Herr Chair in Pediatric Oncology Research and Professor, Departments of Biochemistry & Molecular Biology and Pharmacology & Toxicology, Director, Program in Pediatric Molecular Oncology & Experimental Therapeutics, Indiana University School of Medicine. He is also the Associate Director, Herman B Wells Center and the Associate Director for Basic Science at the IU Simon Cancer Center. Dr. Kelley has a PhD from LSU and postdoctorate at The Rockefeller University. He has published over 170 peer-reviewed articles, 30 reviews/book chapters and has 11 patents. He also edited both editions in DNA Repair in Cancer Therapy: Molecular Targets and Clinical Applications.
Dr. Lariccia received his Ph.D. degree in Neuroscience from the University “Federico II”, Naples, Italy. He joined as Assistant Professor of Pharmacology the University “Politecnica delle Marche”, following completion of his studies on the regulation of Na-transporters by surface membrane turnover with Dr. Donald W. Hilgemann at the UTSouthwester, Dallas. Dr. Lariccia use electrical and optical methods to investigate the regulatory processes that govern the activity of Na-transporters, recently with a focus on the functional interaction between NCXs and glutamate transporters from EAAT family.
Sichuan University, China (BS, 1990), Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences (MS, 1993; Ph.D. 1996), NIH (Post Doct. 1997-2000), Shanghai Institute of Materia Medica, Chinese Academy of Sciences (full professor, 2001-2017). From April 2017, Dr. Long joined Soochow University Medical College in Suzhou, China as the distinguished professor and vice dean. She has published more than more than 90 scientific publications and is a named inventor of 20 issued Chinese patents and 2 U.S patents. Research Interests: (1) Medicinal chemical biology, and (2) Design, synthesis and structure-function relationship study of antivirals and antitumor agents, and (3) green chemistry construction of privileged structure and natural product fragment-based focused library.
Dr. Maksay received his Ph.D. in 1976 from Eötvös University of Sciences, Budapest, Hungary. His previous affiliations: Department of Molecular Pharmacology, Institute of Biomolecular Chemistry, Chemical Research Centre (1973-2011, from postdoc up to head of department); Research Group of Functional Pharmacology, Institute of Molecular Pharmacology and Institute of Organic Chemistry, Research Centre for Natural Sciences (senior research adviser, 2011-2015). He has retired as a research professor emeritus of the Hungarian Academy of Sciences. Research interests: receptorology; structure-activity relationships; ionotropic neurotransmitter receptors (GABAA, glycine, 5-HT3); allosteric modulation; recombinant receptors and voltage-clamp electrophysiology; receptor modeling; structural biology and symmetry violations of signalling complexes. He is Editorial Board member of the journal of the Hungarian Biochemical Society and of the World Journal of Pharmacology.
John L. Nitiss PhD is a professor of Pharmacology and Assistant Dean for Research at the University of Illinois College of Pharmacy. Prior to joining the University of Illinois in 2011, Dr. Nitiss was in the Molecular Pharmacology Department at St. Jude Children’s Research Hospital (1994-2011) and the Department of Pediatrics and Biochemistry at the University of Southern California (1989-1994). He received his PhD in 1986 from the Illinois Institute of Technology in 1986, and carried out postdoctoral work under the direction of James Wang at Harvard University (1987-1989). His laboratory studies DNA topoisomerases as targets of anti-cancer drugs and mechanisms of DNA repair.
Dr. Steven Christopher O’Reilly, Ph.D., is currently a Senior Lecturer of Immunology in the Faculty of Health and Life Sciences, at Northumbria University, UK. His skills and expertise mainly lie in the subject areas of Rheumatology, Immunology, Clinical Immunology, Internal Medicine (General Medicine), Neurology, Diabetology, Pediatrics, etc. Dr. O’Reilly has been awarded funding from the likes of Rosetrees Trust (August 2016-2017), JGW Patterson Foundation (September 2016-2017) and North East Skin Research Fund (2018) for different researches.
Prof. Pedro F. Oliveira was conferred his Biochemistry degree in 1996 at University of Porto. In 2004 he was conferred a PhD degree in Biomedical Sciences at the Institute for Biomedical Sciences Abel Salazar (ICBAS), University of Porto, where he did a Post-Doctorate on Reproductive Biology. Presently, he is a Principal Researcher at i3S – Instituto de Investigação e Inovação em Saúde and a Professor at ICBAS, University of Porto. His main research interests are Biology of Reproduction, Urology, Andrology and Biochemistry, with a particular emphasis on the metabolic modulation of spermatogenesis. His contribution to these research fields has been recognized with the attainment of several research grants and with the invitation to publish in a number of leading journals.
Dr. Hany A. Omar received his Ph.D. degree in 2010 from the Ohio State University, Columbus, Ohio, USA. Dr. Omar is currently an Associate Professor of Molecular Pharmacology and Therapeutics in the Department of Pharmacy Practice and Pharmacotherapeutics (College of Pharmacy) at University of Sharjah, UAE. He is an author/co-author of over 70 scientific articles. His research focuses on the molecular mechanisms of anticancer drugs with a special focus on the treatment of hepatocellular carcinoma, colon, breast and prostate cancers. Furthermore, his research activities include the determination of anticancer activity and elucidation of molecular targets, safety, and mechanisms of action of novel preclinical anti-tumor agents.
Dr. Pelicano obtained a doctorate (Ph.D.) in Chemistry and biochemistry from the University of Montpellier II, France. Currently Dr. Pelicano is an instructor at MD Anderson cancer center in Houston. Dr. Pelicano’s research focuses on cancer metabolism, oxidative stress, anticancer agents, and novel therapeutic strategies. Dr. Pelicano has published more than 40 peer-reviewed research articles.
(Applied Research using OMIC Sciences S.L.
Dr. Plasencia obtained a doctorate (Ph.D.) in Medicine and surgery from the University Autonoma of Barcelona (Barcelona, Spain). Dr. Plasencia also holds an Executive Masters in Biotechnology from Genoma España and is currently finalizing the Executive Master in Business Administration from EAE business school (Barcelona). Currently Dr. Plasencia is co-founder and chief executive officer of the small biotech Applied Research using Omic Sciences (Aromics S.L.) and co-founder and chairman of the board of Aesis Therapeutics (Italy) and Acceleromics (Spain). All three biopharmaceutical companies are devoted to the development of novel antitumor and antiviral agents. She has scientific publications in international journals and currently acts as European expert for European Commision R&D programs.
Dr Philippe Pourquier obtained a doctorate (Ph.D.) in Biochemistry and Molecular Biology from the University of Bordeaux, France. Dr Pourquier also holds a Pharmacy Doctorate from the same University. Dr Pourquier is currently a Research Director at the french National Institute of Health and Medical Research (INSERM) in the research unit U1194 in Montpellier, France. Dr Pourquier acquired a solid experience in the field of drug resistance to anticancer agents, in particular DNA topoisomerases’ inhibitors and has published more than 60 papers in this field. He is developing basic and translational research programs to identify alternative therapies for the treatment of castration-resistant prostate cancers.
My research interest was focused on new therapeutics strategies in cancer treatment. I studied Biochemistry at University of Basque Country (1992 – 1997) and obtained my PhD (1998 - 2002) in the Spanish National Research Council (IIB-CSIC). I was a junior scientist at the Department of R&D at Pharmamar Inc. (2003 - 2004), and at University of California Los Angeles (UCLA) (2005-2008). In 2009, I joined to DKFZ (German Cancer Research Center) in the division “Systems Biology of Signal Transduction”, as a project manager for LungSys consortium (2009-2015). Currently I am employed by German Center for Lung Research (DZL), in the multidisciplinary group of Lung Carcinoma.
My studies focus on clustering of molecular partners in defined subcellular compartments (signalosomes) that enable cells to exert highly specialized tasks. Current studies on the organization of signaling components within functional units and how novel pathways regulate physiological processes in cell, tissue and organ systems engage research areas of integrative pharmacology and translational medicine within a multidisciplinary approach with local, national and international collaborators. We apply for example precision cut tissue slice organ-on-a-chip techniques. I very much enjoy collaborations and the opportunity to work with others and to excite young people about research.
Arne Schousboe obtained his M.Sc. in biochemistry from The University of Copenhagen in 1968 at a time where an M. Sc. was considered equivalent to a Ph.D. He subsequently (1978) earned his Doctor of Science (D. Sc.) degree also from University of Copenhagen. In 1990 he moved to the Royal Danish School of Pharmacy, Copenhagen as a Full Professor of biochemistry. He has served as the Department Chair from 2005 to 2010 and is now part time Professor of Neuropharmacology in Department of Drug Design and Pharmacology at University of Copenhagen. He has published over 550 papers on these and related topics.
Dr. Stern received her undergraduate training in Biology from School of Sciences, University of Buenos Aires, Argentina. Her study focus in University of Buenos Aires was on molecular and evolutionary genetics. She later obtained her PhD in Cancer Biology at the University of Texas-MD Anderson Cancer Center and pursued postdoctoral training in molecular epidemiology from the National Institutes of Environmental Health Sciences, National Institutes of Health. At USC, she is currently a Professor in the departments of Preventive Medicine and Urology in the Keck School of Medicine. Dr. Stern overall research interests are in the following main areas: diet and cancer, clinical epidemiology of prostate cancer, and cancer health disparities in Latino populations.
Dr. DaLiao Xiao obtained a Ph.D. degree in Pharmacology from Loma Linda University School of Medicine, California. Dr. Xiao is an associate professor in the Center for Perinatal Biology, Loma Linda University, California, USA. Dr. Xiao’s research is mainly focusing on the fetal programming of cardiovascular system in response to in utero adverse environmental exposure. He and His research group try to understanding of the epigenetic mechanism and identify the epigenetic biomarkers during early life that have diagnostic value to predict the consequences of in utero adverse environmental exposure induced cardiovascular disease in adulthood. He has published more than 70 peer-reviewed scientific publications. His research projects are constantly supported by NIH and California State grants.
Dr. Cheng-Chia Yu is a professor of Institute of Oral Sciences, College of Oral Medicine at the Chung Shan Medical University in Taiwan. Dr. Yu obtained his Ph.D. degree and completed the postdoctoral training at the Institute of Oral Biology, School of Dentistry, National Yang-Ming University in Taiwan. He serves as visiting professor at Harvard Medical School & Brigham; Women’s Hospital from 2018- 2019. Research in his laboratory mainly focuses on the therapeutic development on targeting oral cancer stem cells and oral submucous fibrosis. He also serves as an Academic Editor or Editorial Board member for other scientific journals, such as Frontiers in Oncology, J Clin Med., Nutrients, Int J Mol Sci, PLOS ONE, and Int J Dent. His remarkable work has attained Ministry of Science and Technology Special Outstanding Talent Award since 2002 in Taiwan.
Dr. Andrey A. Zamyatnin Jr. is currently a Professor, Head of the Institute of Molecular Medicine in Sechenov First Moscow State Medical University, Moscow Russia. He earned his PhD in Virology and later DSc in Virology and Molecular Biology in Lomonosov Moscow State University. His current research interests are molecular markers, molecular targets, development of immunotherapy and enzymatic therapy approaches. Additionally his research interests include programmed cell death, RNAi, virus-host interactions. His scientific publications include more than 50 articles in peer-reviewed journals. Dr. Zamyatnin acts as an Expert in several scientific funds.
Dr. Naiming Zhou received his doctoral degree in molecular biology from Zhejiang Agricultural University in 1993. His postdoctoral work was done at KU Leuven, Belgium, and at Thomas Jefferson University, Philadelphia, respectively. In 2002, he joined Incyte Corporation, Delaware, where he was involved in drug discovery projects. Afterward, he returned to the Zhejiang University where he has been appointed Professor of Biochemistry and Molecular Biology in 2006. Dr. Zhou has published more than 60 peer reviewed SCI papers and awarded 5 patents.
Dr. Weiguo Huang is currently a Associate professor, Cancer Research Institute of Hengyang medical college, University of South China. He received his MD (2004) degrees in Pathology and Pathophysiology, University of South China, Hengyang. And he received his PhD (2010) degrees in Pathology and Pathophysiology, Key Laboratory of Cancer Proteomics of Chinese Ministry of Health, Xiangya Hospital, Central South University, Changsha. Major in clinical pathology, genomics, proteomics, molecular biology and bioinformatics. His current research interests are Carcinogenesis, Diagnosis, and Molecular Targeted Treatment for Nasopharyngeal Carcinoma.

industry_corpus2: Health & Medicine


text:
Our client, a leader in the entertainment industry, is hiring a PHP Architect. This is a full-time position located to the south of the City of Pittsburgh. This is an exciting opportunity to join our small Software Development team in Pittsburgh. The responsibilities of this position include a mix of current product enhancements and new project work. LAMP stack experience is essential. Building tools to support the business needs is a core focus of the operation. The ideal candidate can work independently, while performing as part of a larger development team.
Accurately track issues and resolutions using internal tools.
Provide updates and transparency to management.
Comfortable working with Linux and Apache.
Understanding of SOAP and RESTful web services.

industry_corpus2: Computing & Telecommunications


text:
Poor Konrad Spitzbart. As Executive Pastry Chef at the Peabody Hotel in Memphis, Spitzbart was given a tough task recently when the Association of Food Journalists convened at his hotel. His audience of 125 food writers, editors, cookbook authors and bloggers had just returned from a fabulous, multi-course luncheon of vegetarian soul food at Felicia Suzanne’s restaurant in downtown Memphis. And they were due to attend AFJ’s annual multi-course Awards Banquet just a few hours hence.
Spitzbart was challenged to wow them during the hotel’s mid-afternoon “coffee break,” serving a “little something” between the two heavyweight feasts.
But, hey, a little homemade maple ice cream, laced with bacon bits, doesn’t do a peach pie any harm, does it? Apparently not, because I saw nary a soul turn down the creamy wonder being scooped personally by Spitzbart. Then there were the shot glasses filled with Jack Daniel’s Caramel Sauce, all lined up on a table nearby, begging to be slurped. How luscious was that? Well, let’s just say that not everyone got his/her portion because after I poured one shot on my peach pie and tasted it….I grabbed another shot and downed it neat. That luscious!

industry_corpus2: Hospitality & Catering


text:
The support which Nova provides for organisations.
We support groups and organisations to achieve their aims and grow.
We work with our Nova Partners to achieve this: Community Foundation for Wakefield District, PERS, WYCAS and Young Lives, and other organisations when required.
To enable organisations (whatever size) to make their own informed choices with all the appropriate structures in place.
Nova members can access Nova Assist, an online diagnostic tool to help groups understand the strengths and weaknesses of their organisations. Your group can carry this out themselves, or ask someone from Nova to go through it with you.
Once you understand your organisation's development needs, we can offer 1-2-1 support. This includes advising you on how your organisation operates, how to ensure that you are carrying out your activities safely & legally, and how to plan for the future and grow your organisation.
Some of this we can provide free of charge and some we charge for.
If we can't help you, we can signpost you to other specialist support.
We want to reach as many people as possible, so we also offer support via training and events.
Nova is a membership-led organisation therefore your input about what you need and want is important to our delivery service. We want to provide you with the best support we can!
For more information, please contact one of our specialist Nova Advisers by calling 01924 367418. Alternatively, you can find all staff emails here.


text:
Yesterday we asked what your significant other drives, but what about that other significant other in your life? The one who brought is into this world and threatens to take us out of it? What's your mom's car?
What Does Your Significant Other Drive?
Wert's mom used to drive an old MG, an old VW Bug and the eighth Chrysler Sebring convertible ever built. Now she's a certifiable Bimmerphile, driving a Z4 in the summer and, against her son's protestations, an X3 in the cold winter months. My mother drives a 3-series, but of the Mazda variety. All of Wojdyla's women like tiny Japanese cars, so his mom is rocking a Toyota Corolla. The mysterious mom of The Auto Insider rocks the GMC Acadia. Even Siler's family is committed to making the rest of us look bad. His mom drives an A4 Avant with a turbodiesel and six-speed manual.
What does/did your mom drive? Bonus points to anyone who's mom still has an LT1-powered Roadmaster Estate with wood paneling.

industry_corpus2: Automobiles


text:
Unix forms a foundation that is often very helpful for accomplishing other goals you might have for you and your computer, whether that goal is running a business, writing a book, curing disease, or creating the next great app. The means to these goals are sometimes carried out by writing software. Software can’t be mined out of the ground, nor can software seeds be planted in spring to harvest by autumn. Software isn’t produced in factories on an assembly line. Software is a hand-made, often bespoke good. If a software developer is an artisan, then Unix is their workbench. Unix provides an essential and simple set of tools in a distraction-free environment. Even if you’re not a software developer learning Unix can open you up to new methods of thinking and novel ways to scale your ideas. This course is intended for folks who are new to programming and new to Unix-like operating systems like macOS and Linux distributions like Ubuntu. Most of the technologies discussed in this course will be accessed via a command line interface. Command line interfaces can seem alien at first, so this course attempts to draw parallels between using the command line and actions that you would normally take while using your mouse and keyboard. You’ll also learn how to write little pieces of software in a programming language called Bash, which allows you to connect together the tools we’ll discuss. My hope is that by the end of this course you be able to use different Unix tools as if they’re interconnecting Lego bricks.
This week we'll help you get access to Unix (you may already be using it), and you'll start using the command line. We'll draw parallels between using your mouse and keyboard with your computer's graphics versus only using the command line.
Hello and welcome to week one of The Unix Workbench.
the Data Science Lab at the Johns Hopkins Bloomberg School of Public Health.
our personal computers, and even our phones.
Unix tools even if you've no prior programming experience.
Unix and how to start using the command line.
including how to improve online education.
See you in the forums and good luck with the first week.

industry_corpus2: Programming


text:
Terrorism is a tool and a verb. It is not something that is a tangible entity and so therefore one cannot wage a conventional war against it. By doing so it enables the people in power to fight a war for whatever reason they choose to with the outward appearance of moral justification to the general population. This is so because of the harsh connotations associated with terrorism and the fear it invokes in people. By playing off of people’s fears it is letting terrorists win and by fighting a conventional war it makes the conditions that produce terror in the first place more prevalent. This is a vicious cycle and it must be broke somehow.
The fact is if a group of people wants to kill others they can. A rogue act by an individual or a few people against others cannot be stopped. Think about it: if you wanted to perform an act of violence on your fellow man couldn’t you do it if you really wanted too? The only way you could stop events like this would be to live under a totalitarian rule where the very rights you hold to be self evident are put on the back burner for security. Even then you would still have the occasional wing-nut or two slip through the cracks of the system. The way you fight terrorism is by making the underlying motivations for it to become null and void. You do this through the principles of what made this country great to begin with, egalitarian compromise and open debate. This is the complete anti-thesis of how this “War on Terror” is being fought and it almost seems intentionally so.
Terrorist do not fight because they hate our freedom or for any other jingoistic factor. The reason why they attack us or other groups of people is because they have a political agenda whose needs are not being met. People are inherently good, including terrorists, and will not fight unless they have a legitimate reason to do so. Usually when a group resorts to violence it is because one or more of their basic human rights are being violated. This is universally true in almost all instances of terror and all one has to do to understand this is to try to be objective and put themselves in the other person’s shoes and ask themselves what they would do if they were in that situation. I dare any person to try to empathize with the average Palestinian and ask themselves if they would not do the same if they were dealt the same cards in life. All but the most Ghandi or Christ-types would. I am sorry Israel. I love you but I must ask these tough questions as your very survival as a nation depends on it and if your current methods for fighting terror do not stop your nation in its present form will not exist in the not too distant future. This is simply the objective truth and I do not want to see this happen. You can call me an anti-Semite all you want but with my particular bloodline I know this argument will not work as a house divided against itself will not stand.
I do not ask these difficult questions with a motivation to try to justify terror. I am not. I only ask these questions to try to get people to understand the root causalities of terror with an effort to try to rid the world of them. People will not fight if they have decent paying jobs and are not poor. People will not fight if they have food in their stomachs. People will not fight if they have an opportunity for social advancement. People will not fight if they have an education. People will not fight if they have a decent environment to raise a family. People will not fight if they have endless supplies of free electrical energy to power their industries. People will not fight if their land is not forcefully taken from them. And people will not fight if their land is not under constant occupation.
So by making these conditions manifest in the world is the real way you fight terror. By doing what we are doing in this country will only make these conditions worse and it will only increase terror for years to come. We are losing this war because we are going about fighting it in the wrong way and we are less safe three years after 9-11 for doing it. What kind of a world will our children have if the people in power have their way by waging a hundred year war on terror? Will it be a world worth living in?
Besides these obvious contradictions with the broad definition of WMDs there are also legitimate weapons that would fall under a more rational definition, but these to cannot really be stopped unless the human rights are squashed on a global level. The information on exotic WMDs of all types are all over the place and the variations on a theme are limited to only one’s imagination. Any half decent science hack can figure it out and they eventually will. This is again just reality speaking and this is what is starting to be seen in Israel with the Qusaam rockets and this general trend will escalate in years to come. Pretty soon within the next thirty years just about any country with a lab of a few hundred thousand dollars will have a real WMD in some form or another. The only way to stop this would be to take away essential liberties to the point that the world would literally be divided into a two tiered social structure and this still would not stop it completely. The age old Marxist have vs. have-not dichotomy would then be taken to the level of a global police state. This of course is an extreme picture but yet if you take the logical premises of the current administration’s policies at face value this is the only end result that can happen if you want to try to fight terror in the manner they are doing it. So what is the end game and where are we going with all of this? Is this current foreign policy one of vision as it is being marketed or is it one of temporary consolidation of world resource power? To answer this question I would ask the reader to take the position of a Haliburton or Carlyle Group executive.
n all its forms and bring this world closer to the place God intended.


text:
When you run an analysis module, visualization module, or pipeline, GenePattern displays the parameters for the selected modules. Often, one or more of these parameters are input files, which must have a particular format; for example, you might need to supply a gct or res file. For more information about a particular file format, select it from the list at the right.
This section provides general information to help you create properly formatted files for GenePattern.
Additional resources are available from our partnered site GenomeSpace. Their Convert file formats page lists supported file conversions, descriptions of file types, and an email to request new file format converters. Check their blog for newly added converters.
Although different GenePattern modules require different file formats, all of the files are plain text files. Plain text differs from rich text as described in Wikipedia, and these cannot be interchanged.
Data within files are parsed in various ways, e.g. tab-delimited, space-delimited, comma-separated, or one item per line. Most gene expression data is tab-delimited and you can open the file in a spreadsheet or database program that allows you to export the data into a plain text file. To transvert a plain text file to a specific format, e.g. GCT or CLS, the contents must conform to the attributes of the format as described and have the correct file extension. Required attributes include a specific delimiter, e.g. tab, specific usage for select cells, e.g. headings and numeric tallies, and/or unique sample and probe identifiers. File extensions appended to the end of a file are recognized by GenePattern modules, start with a period, and are typically three letters, e.g. dataset1.gct or dataset1.cls.
Multiple modules exist under Data Format Conversion and Preprocess & Utilities that transform plain text files to specific formats, e.g. Read_group_trackingToGct, help create supporting files from such expression files, e.g. ClsFileCreator, or process files in desired ways, e.g. UniquifyLabels and SelectFileMatrix.
Open the data file in a text editor or spreadsheet editor.
Keep in mind some spreadsheet programs convert gene symbols to dates, e.g. Excel converts MARCH1 to 1-Mar, as well as introduce other irreversible auto-formatting conversions as described in Zeeberg, et al (2004). Avoid these conversion by using Excel's Text Import Wizard, e.g. via File>Import. In the third step of the Text Import Wizard, highlight the column(s) and select Text as the Column data format instead of the default General.
Use Excel's Text Import Wizard to convert space delimited files to spreadsheet format, i.e. select Delimiters>Space, and to split labels separated by a longbar (|) into two columns, i.e. select Delimiters>Other: and type | in the textbox.
Make the necessary changes that conform to file format attributes described on this page and save as a plain text file.
Excel's Save As>Tab delimited text and Comma Separated Values save as plain text with TXT and CSV extensions, respectively.
For a space-delimited file, open the CSV file with a text editor and find and replace each comma with a space.
Mac's TextEdit defaults to rich text format. Change this for the current document by selecting Format>Make Plain Text, and for future documents by setting TextEdit>Preferences>Format to Plain text.
Change the file extension to the appropriate extension, e.g. GCT or CLS.
In Mac OS, to change the file extension, right-click on the file>Get Info, expand Name & Extension section, uncheck Hide extension option, then change the extension in the box provided.
In turn, open these plain text format files using (1) the Open with function and selecting a text editor, (2) adding a .txt extension to the end and doubling-clicking, or (3) importing into a spreadsheet program, e.g. Excel.
Review the GCT and RES Files page of the GenePattern protocols.
The Modules page of the GenePattern web site provides a complete list of the modules and pipelines available from the Broad Institute. Modules in the Data Format Conversion category convert files from one format to another. Modules in the Preprocess & Utilities category provide methods for importing and working with data files.
Save the sample.cdt file to your local drive and open it in Microsoft Excel.
Delete the CLID and GWEIGHT columns. The gct file format allows for only two columns of annotations.
Delete the second row, which contains array identifiers (AID). The gct file format allows for only one row of identifiers.
Save the modified file as a text (tab delimited) file with the name sample.gct.
Verify that your new .gct file matches the requirements of a gct file in GenePattern.
Your original cdt file contained cells that were missing data. Most GenePattern modules require that all cells in a gct file contain data. Use the GenePattern analysis module ImputeMissingValues.KNN to add the missing data to your gct file. The module will take sample.gct as the input file, impute the missing data, and generate a sample.imputed.gct file.
Note: If you are using Excel to edit GenePattern files, be sure to save the file as a tab-delimited text file and supply the correct file extension. You can specify the file name in quotes to prevent Excel from appending .txt to the file name. Also, note that Excel's auto-formatting can introduce errors in gene names, as described in Zeeberg, et al (2004).
ATR files will be created by the HierarchicalClustering module. This is a format defined at Stanford for their Hierarchical Clustering program. Note that the HierarchicalClustering module will also generate a CDT file.
The ATR (array tree) file records the order in which the arrays (columns) were joined during clustering.
CBS files are created by the CBS module. A CBS (circular binary segmentation) file is a tab-delimited text file with six columns: the sample id, the chromosome number, the map position of the start of the segment, the map position of the end of the segment, the number of markers in the segment, and the average value in the segment. The first row contains column headers and the second row onwards contains data values.
These tree files reflect the history of how the cluster was built, and can be used to reconstruct the tree(s).
Affymetrix image analysis software generates CEL files, which store information about the probes on a chip and the intensity values for the probes. GenePattern modules, such as ExpressionFileCreator and SNPFileCreator, take CEL files as input and generate data files that can be read by subsequent GenePattern modules. More information on this format is available here.
The CHIP file format contains annotation about a microarray (used with GSEA module). It lists the features (i.e probe sets) used in the microarray along with their mapping to gene symbols (when available). While this file is not used directly in the GSEA algorithm, it is used to annotate the output results and may also be used to collapse each probe set in the expression dataset to a single gene vector.
Chip annotation files can be specified in a tab-delimited file format (*.chip) or in a comma-separated file format (*.csv). The formats are identical other than the separation character (tab or comma). Typically, you use the tab-delimited (*.chip) file format.
These three columns can appear in any order. The file may contain additional columns, which will be ignored.
The rest of the data file contains data for each probe set ID used in the microarray.
The CLM file format is a tab-delimited file format that describes the samples in a zipped collection of CEL or IDAT files (used with the ExpressionFileCreator and IlluminaExpressionFileCreator modules, respectively).
The first column contains the CEL file name (file extension is optional).
The second column contains a sample name for the CEL file data.
The third column contains a phenotype class name for the CEL file data.
Categorical labels define discrete phenotypes, e.g. normal versus tumor.
Continuous phenotypes are used for time series experiments or to define the profile of a gene of interest, e.g. gene neighbors.
Note: Most GenePattern modules are intended for use with categorical phenotypes. Therefore, unless the module documentation explicitly states otherwise, a CLS file should define categorical labels. GenePattern's ClsFileCreator module provides a guided wizard to create a CLS file from .gct or .res files.
The first line of a CLS file contains numbers indicating the number of samples and number of classes. The number of samples should correspond to the number of samples in the associated RES or GCT data file.
The second line in a CLS file contains names for the class numbers. The line should begin with a pound sign (#) followed by a space.
The number of class labels specified on this line should be the same as the number of samples specified in the first line. The number of unique class labels specified on this line should be the same as the number of classes specified in the first line.
The first line contains the text "#numeric" which indicates that the file defines continuous labels.
The first line defines the name of the phenotype; for example, #AFFX-BIOB-5_st.
The second line contains a value for each sample in the .gct file. Typically, your word processor wraps the second line of the phenotype definition, as shown in the example.
The first line contains a list of labels identifying the SNP arrays.
The rest of the SNP file contains one row of data for each SNP.
Note: Sort the SNPs by chromosome and physical position (low to high). Most GenePattern modules, as well as many external tools, require sorted data.
Flow Cytometry Standard (FCS) files are used by GenePattern's numerous flow cytometry data analysis and data processing modules. The International Society for Advancement of Cytometry (ISAC) provides detailed resources outlining flow cytometry data file format standards, including for updated FCS formats, as well as example data transformations.
Check module documentation to see which versions of FCS files the module accepts. For example, the FLAME suite modules accept FCS v2.0, FCS v3.0, and TXT files.
In addition to analysis modules, GenePattern offers a number of modules that allow for FCS data manipulation that include CsvToFcs, FcsToCsv, ExtractFCSParameters, FCSNormalization, CompensateFCS, and PreviewFCS.
FPKM_tracking, Count_tracking, and Read_group_tracking files are output by the Cufflinks suite modules, which include Cufflinks and Cuffdiff. For more information on each of these and other Cufflinks suite file types, see the Cufflinks website. You can convert these to GCT format using Fpkm_trackingToGct or Read_group_trackingToGct modules.
13 q0_status OK Quantification status for the object in sample 0. Can be one of OK (deconvolution successful), LOWDATA (too complex or shallowly sequenced), HIDATA (too many fragments in locus), or FAIL, when an ill-conditioned covariance matrix or other numerical exception prevents deconvolution.
17 q1_status 9.32617 the upper bound of the 95% confidence interval on the FPKM of the object in sample 1. Can be one of OK (deconvolution successful), LOWDATA (too complex or shallowly sequenced), HIDATA (too many fragments in locus), or FAIL, when an ill-conditioned covariance matrix or other numerical exception prevents deconvolution.
3N + 15 qN_status OK Quantification status for the object in sample N. Can be one of OK (deconvolution successful), LOWDATA (too complex or shallowly sequenced), HIDATA (too many fragments in locus), or FAIL, when an ill-conditioned covariance matrix or other numerical exception prevents deconvolution.
8 effective_length 5988.24 The effective length of the object in this replicate. Currently a reserved, unreported field.
9 status OK Quantification status for the object. Can be one of OK (deconvolution successful), LOWDATA (too complex or shallowly sequenced), HIDATA (too many fragments in locus), or FAIL, when an ill-conditioned covariance matrix or other numerical exception prevents deconvolution.
The GCT file format is a tab delimited file format that describes an expression dataset. The main differences between RES and GCT file formats are the RES file format (1) contains labels for each gene's absent (A) versus present (P) calls as generated by Affymetrix's GeneChip software and (2) does not allow missing expression values. Although the GCT file format allows missing values, only a few modules (such as CART, GSEA and HierarchicalClustering) can be run against an expression dataset that is missing values. Most modules do not allow missing expression values.
The second line contains numbers indicating the size of the data table that is contained in the remainder of the file. Note that the name and description columns are not included in the number of data columns.
The third line contains a list of identifiers for the samples associated with each of the columns in the remainder of the file.
The remainder of the data file contains data for each of the genes. There is one line for each gene and one column for each of the samples. The first two fields in the line contain name and descriptions for the genes (names and descriptions can contain spaces since fields are separated by tabs). The number of lines should agree with the number of data rows specified on line 2.
Occasionally, GCT files are organized in a transposed structure where the columns represent genes and the rows represent samples. The user should take care to check the organization of the file to ensure that the correct preprocessing is performed on the file. See sample *.gct files that come with the distribution for complete examples of the format.
The first line contains a list of labels identifying the columns.
The rest of the file contains one row of data for each altered chromosomal region.
The first column contains the gene set name. Duplicate names are not allowed.
The second column contains the gene set description. GSEA uses the description field to determine what hyperlink to provide in the report for the gene set description: if the description is na, GSEA provides a link to the named gene set in MSigDB; if the description is a URL, GSEA provides a link to that URL.
The remaining columns list the genes in the gene set.
The first line contains the gene set name. Duplicate names are not allowed.
The second line contains the gene set description. GSEA uses the description field to determine what hyperlink to provide in the report for the gene set description: if the description is na, GSEA provides a link to the named gene set in MSigDB; if the description is a URL, GSEA provides a link to that URL.
The remaining lines list the genes in the gene set.
The GRP file format contains a single gene set in a simple newline-delimited text format. Typically, you use the GMT or GMX file formats to create gene sets, rather than using the GRP file format. The GRP format contains a line for each gene, one gene per line. Lines that start with a pound sign (#) are ignored.
GTR files will be created by the HierarchicalClustering module. This is a format defined at Stanford for their Hierarchical Clustering program. Note that the HierarchicalClustering module will also generate a CDT file.
The GTR (gene tree) file records the order in which the genes (rows) were joined during clustering.
The first line contains a list of labels identifying the paired samples.
The rest of the SNP file contains one row of data for each probe.
MutSigCV and ABSOLUTE modules utilize Mutation Annotation Format (MAF) files. A MAF file is a tab-delimited plain-text file that notates mutation or variation against a reference genome. The file lists one mutation per row, gives information about the mutation in the columns, and has a header row that labels the columns. The National Cancer Institute's wiki on TCGA (The Cancer Genome Atlas) gives format specifications.
GenePattern modules utilizing MAF files require specific mutation information columns with specific column header labels. See the Input Files section of documentation for each module for the necessary columns. For example, MutSigCV MAF files must contain two nonstandard columns of effect and categ in addition to the columns gene and patient. A tab-delimited plain-text file containing only these four columns is sufficient to run the module.
The MAGE-TAB and MAGE-ML file formats are defined by the Functional Genomics Data Society (FGED, formerly MGED) to create standards for the representation of microarray expression data to facilitate the exchange of microarray information between different data systems. More information about and sample files in the FGED-based formats are available here.
The Ouput Description Format (ODF) is similar to the RES or GCT file formats for datasets. The main difference is in the header. The body of data still contains the expression level values for each gene in each sample. Thus the main data block (after the header lines) is a matrix of values. The columns are defined by a name and optionally a description. The rows have a name (name of the gene for instance) and a description (description of the gene). The columns contain the expression values for each gene in a sample. If the first gene in the data block is a particular Tyrosine Kinase then each of the samples contained in each of the columns will have expressions values for that particular Tyrosine Kinase in the first row.
Note: This ODF format is specific to GenePattern. It is not an Open Document Format (ODF) for Office Applications as defined by the Organization for the Advancement of Structured Information Standards (OASIS).
The following example shows the header lines of an ODF file. The first five lines are required.The line numbers are shown for easy reference, they should not be included in your file.
Lines 1 and 2 are required first and second lines. They must both be present in the header and be the first and second lines. They signify that this is an ODF formatted file (of type 1.0) and indicate the number of header lines that follow before the main data block (in this case 7 more). Line 3, required to be somewhere in the header of an ODF file, defines this ODF file as containing Dataset data. Line 4 is required somewhere in the header file. It indicates the number of data rows present in the data block. Line 5 is required somewhere in the header file for any ODF file that has a main data block. It defines the type of data in each column. Line 6 is a tab-delimited list of descriptions for each column. Line 7 is a tab-delimited list of names for the columns. Line 8 defines which column will have the row names, and Line 9 defines which column will contain the row descriptions.
The first element of each header line will be a key word. The keyword defines/describes what kind of meta data will be found on the rest of that line.
A remark is a human readable comment that is skipped by the parser. This line starts with the "#" character and can contain any type of text since it is not parsed. Note that remarks are not counted as header lines and the user can insert them "by hand".
The number of data lines can be quite large. For example, the U133A chip measures the expression values for about 20,000 human genes. A Dataset created from several samples using the U133A gene chip could have a large value for the DataLines tag.
The COLUMN_NAMES:, COLUMN_DESCRIPTIONS:, and COLUMN_TYPES: lists must have the same number of elements. Also the number of elements must be equal to the number of columns in the main data block.
The COLUMN_NAMES:, and COLUMN_DESCRIPTIONS: could be empty, that is simply contain the proper number of tabs but no text.
The main data block must be consistent with the header. The first COLUMN_NAMES element is "Name". This label is associated with the first column (values: 1000_at, 1001_at, and 1002_f_at). The second column's label is "Description" which is associated with the second column of the main data block. The next three columns are floating point numbers that represent the gene expression values for each of the samples.
Note: The first two columns are just text data, and next three columns only contain floating point values. This is consistent with the "String, String, float, float, float" elements in the COLUMN_TYPES: list.
PCL files may be used as input for the GSEA module. This is a format defined at Stanford for their CDNA expression data. More information on this format is available here.
The first line contains a list of labels identifying the samples associated with each of the columns in the remainder of the file. Two tabs (\t\t) separate the sample identifier labels because each sample contains two data values (an expression value and a present/marginal/absent call).
The second line contains a list of sample descriptions. Currently, GenePattern ignores these descriptions.
The third line contains a number indicating the number of rows in the data table that is contained in the remainder of the file. Note that the name and description columns are not included in the number of data columns.
The rest of the data file contains data for each of the genes. There is one row for each gene and two columns for each of the samples. The first two fields in the row contain the description and name for each of the genes (names and descriptions can contain spaces since fields are separated by tabs). The description field is optional but the tab following it is not. Each sample has two pieces of data associated with it: an expression value and an associated Absent/Marginal/Present (A/M/P) call. The A/M/P calls are generated by microarray scanning software (such as Affymetrix's GeneChip software) and are an indication of the confidence in the measured expression value. Currently, GenePattern ignores the Absent/Marginal/Present call.
The first line contains the column labels. A sample information file can contain any number of columns and the column labels are arbitrary. However, SNP modules may require specific labels, as discussed below.
The remainder of the sample information file contains a line of information for each SNP sample. Where data is unavailable, columns may be empty.
Array: Identifier for the SNP array.
Sample: Identifier for the biological sample used to generate the SNP array data.
Type: Brief description of the biological sample.
Ploidy(numeric): Integer value, where ploidy=2 indicates a normal sample.
Gender: Identifier that indicates the gender of the biological sample donor. For a sample from a male donor, Gender=M; from a female donor, Gender=F.
Paired: Value that identifies normal-target pairs. For the normal sample, Paired=Yes; for the target sample, Paired is set to the sample name of the paired normal sample.
Platform: SNP chip used to generate the array.
Note: When a SNP module requires a sample information file to include specific column labels, the module documentation lists the required column labels. Specify required column labels exactly: they are case-sensitive and space-sensitive.
The following steps outline how to copy exactly sample identifiers from Excel data and tranpose them from horizonal to vertical.
In Excel, Select entire row containing sample names and Copy. Open a new workbook, Paste Special>Transpose.
If starting from a RES file, to remove blank rows, Select relevant column(s), then click Edit>Go To>Special button>Blanks option and click OK. Blank rows will be selected. Choose Edit>Delete>Entire row option and click OK.
Label row headings exactly as specified for module, fill in cells, and save as tab delimited text (.txt). For example, ComBat module labels first three cells of Row 1: “Array”, “Sample”, and “Batch”.
This is a tab-delimited file format that contains SNP array data. The SNPFileCreator module can create non-allele-specific SNP files or allele-specific SNP files. A SNP file contains one row for each SNP and two or three columns for each SNP array. Non-allele-specific files contain two columns for each SNP array: the intensity value and the call. Allele-specific files contain three columns for each SNP array: the intensity value for allele A, the intensity value for allele B, and the call. Note: Not all SNP modules accept allele-specific SNP files.
The first line of a SNP file contains a list of labels identifying the SNP arrays. The rest of the SNP file contains one row of data for each probe. Each row contains the probe intensity values and the SNP calls generated by the SNP microarray scanning software, such as Affymetrix's GeneChip software, as shown in the examples below.
Non-allele-specific files contain two columns per sample.
Allele-specific files contain three columns per sample--an intensity value for each of the two alleles and a call.
The first line contains the labels Name and Description followed by the identifiers for each sample in the dataset. The Description is optional.
The remainder of the file contains data for each of the genes. There is one line for each gene. Each line contains the gene name, gene description, and a value for each sample in the dataset. If the first line contains the Description label, include a description for each gene. If the first line does not contain the Description label, do not include descriptions for any gene. Gene names and descriptions can contain spaces since fields are separated by tabs.
The rest of the SNP file contains one row of data for each probe, including the raw copy number value and the SNP calls generated by SNP microarray scanning software (such as Affymetrix's GeneChip software). Some modules, such as the SNPViewer module, require the data sorted by chromosome and physical position.

industry_corpus2: Technology & Research


text:
We are pleased to announce the third call for Doctoral Training Partnerships.
Investments in doctoral training are a key component of UK Research and Innovation (UKRI) and the Biotechnology and Biological Science Research Council’s (UKRI-BBSRC) overarching goals to develop research talent and skills. UKRI-BBSRC‘s vision is for an innovative, inclusive and outcomes-focussed programme of doctoral training to build and maintain the capacity of bioscience disciplines, and deliver skills for impact across the UK economy.
UKRI-BBSRC Doctoral Training Partnerships (DTP) provide PhD training in areas of research relevant to UKRI-BBSRC’s remit and priority research areas. DTPs also provide a breadth of professional development training opportunities to enhance the capabilities of doctoral candidates and develop a world-class, highly skilled workforce for the UK.
Deliver evidence-based impact from its public investment.
It is anticipated that up to 15 DTPs will be awarded. Total funding of £170 million is available to support up to 340 four-year studentships per annum, including at least 90 CASE studentships, for five consecutive intakes, the first being in 2020-2021 and the final cohort commencing in 2024-2025. The first three intakes are guaranteed; the final two intakes will be dependent on the outcome of a mid-term review. Awards will be made in the form of single profiled training grants. The normal flexibility of UKRI training grants will apply, enabling institutions to part-fund studentships from other sources.
Partnerships will be able to apply for an allocation of standard and collaborative studentships, fully justifying how these studentships will be utilised. The panel will judge each bid for these separately as part of the allocation process.
The funding for each four-year studentship will include £5,000 p.a. research training support costs, as well as student stipend and fees at standard research council levels. Each doctoral candidate will take a three-month internship during their PhD, to experience working in an area not directly related to their PhD project.
All UK based research organisations, or consortia, that are eligible to receive UKRI funding for research, have the infrastructure in place to deliver doctoral training and hold a summed minimum of £20 million UKRI-BBSRC research grant spend over the three year period of 2015/16 to 2017/18, will be eligible to submit a proposal for a DTP.
Non-eligible institutions/organisations may be included as ‘Associate Partners’ on a DTP application, providing the partnership can demonstrate that there is significant added value/benefit to the inclusion of these ‘Associate Partners’ within the partnership. Further details are available in the full call text (see application downloads below).
BBSRC research grant spend from non-eligible institutions/Associate Partners will not count towards the minimum threshold.
Research organisations may only submit one proposal as lead applicant. A DTP mustinclude at least one degree-awarding research organisation within the partnership.
The assessment of proposals to become a UKRI-BBSRC DTP, which will include an interview with the management team of the proposed partnerships, will be scheduled for 10-11 July 2019and announcements regarding the allocation of funding are likely to be made by October 2019.
Applicants are strongly encouraged to read in full the call text and all supporting background information in order to better address the requirements of the call. All documentation is available on this webpage to download.
Proposals must be submitted using the Joint Electronic Submission (Je-S) system by 1 May 2019, 16:00.


text:
This elegant White Russian will become a new tradition at holiday family get-togethers, special occasions, après-ski, or anytime that calls for a memorable cocktail.
These muffins are loaded with roasted strawberries and figs and are made without refined sugar, so you can actually eat them for breakfast with coffee and not be on a crazy sugar high.
This pasta with lentil bolognese is made with just a few ingredients that you most likely have hiding in your pantry. It’s perfectly hearty for the next cold day.
You won’t even miss the meat in these jackfruit enchiladas that are filled with spiced and pulled jackfruit with a homemade chipotle enchilada sauce.
Take your hasselback potatoes to a whole new level by cooking them on the grill and serving them with a traditional Spanish romesco sauce.
Sour with a touch of sweet, this nectarine lemonade is sweetened with a touch of maple syrup to create a cool glass perfect for a summer afternoon.
A salty pretzel crust is filled with a rich chocolate and peanut butter filling brought together by creamy coconut milk. A dessert dream that is easy to make, but hard to wait for as it sets.
Originally from the Galicia region of Spain, this nutty dessert is extremely popular and is part of pretty much every restaurant menu across the country.
Make rich, vegan biscotti with coconut milk, hazelnuts, and plenty of dark chocolate. Your morning coffee just got the best sidekick ever.
A paleta is a frozen pop made fresh fruit. Studded with raspberries, these frozen treats are eye-catching.
This gluten-free shepherd’s pie is also vegan and will please all the guests at your holiday or dinner table with its parsnip and cremini filling.
#myhometownguide for the City of Brotherly love directs you to the hidden food gems.
Vegan chocolate tarts topped with a taunting salted caramel.
Pretty enough to be served at your next gathering or as a light snack or dessert, these sweet and tart yogurt bites are a perfect winter refresher beside a fireplace.
Two types of potatoes create a latke-like base to replace the bread in this gluten-free and vegan stuffing that everyone will love.
Homemade ricotta becomes a delicate dessert with an infusion of flavors and a topping of sweet honey, luscious figs and crunchy almonds.
Try this hearty soup full of super nutritional veggies that won’t leave you missing the meat.
You can serve this as a side dish, or make it a one-pot dinner by mixing in your favorite protein.


text: Choice Career Fairs will be in Baltimore, MD on Thursday, October 25, 2012. Meet face-to-face with the hiring decision makers from some of the best employers in Baltimore. We look forward to seeing you at the career fair. Thursday, October 25, 2012 10:30 AM - 14:00 PM Best Western North Baltimore - Towson 1100 Cromwell Bridge Rd Towson, MD 21286 You'll meet face-to-face with hiring decision-makers from some of the areas top employers. Dress professionally and bring plenty of resumes, because they are there to hire. Just walk in and start interviewing, it's that simple. You can save time, money and effort interviewing with multiple companies in one day at one location. Many of these companies have several openings and are eager to meet with you. You will no longer be just a piece of paper, you can get right in front of the decision makers attending this event. Register now and receive VIP access - It's FREE or for more information on the event, visit the Baltimore Career Fair page. We'll see you there.